[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
Osteonecrosis of the jaws in patients on chronic bisphosphonate therapy has been reported in small series since 2003. We present two patients with multiple myeloma who developed osteonecrosis of the jaws on intravenous treatment with zolendronic acid and pamidronate, respectively. The patients were treated with debridement of the involved bone and long-term antibiotic therapy.
Neumann
Bjarne
B
Aalborg Sygehus, Kaebekirurgisk Afdeling og Medicinsk Haematologisk Afdeling, Alborg. bn@aas.nja.dk
Gregersen
Henrik
H
D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007571:Jaw Diseases / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D010020:Osteonecrosis / Q000139:chemically induced* / Q000473:pathology; D000077268:Pamidronate; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate